ABSTRACT
INTRODUCTION
H eterotopic ossification (HO) is the development of lamellar bone outside the normal bony skeleton. 1 This bone tissue may mature by transformation of soft tissue of mesenchymal origin. This abnormal bone growth typically occurs after insult to soft tissue and is a common complication after traumatic brain injury, highenergy trauma, burns, and total joint replacements. 2 For example, HO may occur in as many as 64% of war-related injuries. 3 This impressive rate of HO formation likely is a consequence of the high-energy trauma unique to warrelated injuries. This extraskeletal bone formation, if left untreated, can result in severe pain, limited joint function, joint ankylosis, and other complications. The need for an effective method of prophylaxis is obvious. Review of the literature reveals an obvious deficiency: much effort has been dedicated to prophylaxis of HO in the hip, but there is no consensus for the prophylaxis of HO in the elbow after surgery or in high-risk clinical settings. Guidelines for prophylaxis in the hip may serve as rough guides for treatment in the elbow, but independent research is necessary. Unfortunately, recent well-powered studies specifically address the issue of radiation as prophylaxis for HO in the elbow but directly contradict one another regarding conclusions and recommendations. 4--6 Recent advances in animal models show immense promise in prevention of HO formation, 7 but at the present time only two prophylaxis options are currently available to the surgeon, including nonsteroidal antiinflammatory drugs (NSAIDs) and radiation. Prudent clinical judgment suggests that the use of radiation and NSAIDs are useful prophylactic methods, yet data regarding their suitability, appropriateness, and complication rates are contradictory. 4,6,8--13 Further, a recent publications offer evidence based practices on the surgical management of functionally limiting HO in the elbow, 14, 15 but no consensus exists for the appropriate window of delay before resection is undertaken. As a result, a survey was constructed to determine the current state of elbow HO treatment practices by U.S.-based orthopaedic surgeons. The survey was sent out to the chairman of every orthopaedic residency training program in the United States with the specific direction that the surveys be forwarded to a faculty member specialized in the care of the upper extremity. Admittedly, this group of respondents represents a small fraction of practicing orthopaedists in the United States, but it also represents some of the leaders in this surgical field that help to establish best practice guidelines.
MATERIALS AND METHODS
A survey instrument was developed that addressed the current management practices of HO in the elbow. This survey instrument consisted of three main topical areas: (1) radiation prophylaxis, (2) NSAID prophylaxis, and (3) recommended time-delay between the index event and surgical management of HO in the elbow. The survey form, in its entirety, is provided in Figure 1 . Surveys were mailed to the chairman of every orthopaedic residency training program in the United States, with specific instructions for the survey to be forwarded to a faculty member specialized in the care of the upper extremity.
We distributed 146 surveys and received 47 responses, which equaled a 32% return. Responses were analyzed to quantitatively determine if specific practices exhibited (i) no consensus, (ii) weak consensus, (iii) moderate consensus, or (iv) strong consensus by our community of respondents. A no consensus classification was given to any HO management practice if the proportion of responses was less than 0.5. Weak, moderate, and strong consensus classifications were given if the proportion of responses was between 0.5 and 0.67, 0.67 and 0.75, and greater than 0.75, respectively (Table 1) . Onesided binomial statistical tests were applied to determine the consensus level of each management practice presented in the survey form. In all statistical tests, alpha was set to 0.05. Table 2 and Figure 2 summarize the results of the elbow HO management practices survey. The results indicate that there is a strong consensus (94%) that radiation or NSAIDS should be used to prevent the development of HO in the elbow. Ninety-one percent (strong consensus) of respondents supported the use of radiation, but there was no consensus regarding the radiation dosage level. Seventy-eight percent (moderate consensus) do not fractionate the radiation dose, which was not significantly greater than the hypothesized strong consensus level of 0.75.
RESULTS
Indomethacin prophylaxis was moderately recommended (84%) by respondents, but a strong consensus of respondents (94%) indicated the use of indomethacin or ibuprofen as a prophylaxis for HO in the elbow. However, there was only weak agreement (67%) on how long to prescribe these or any NSAIDS, with the most common response being 1-3 months.
Time-delays for surgical management of HO in the elbow generally showed weak or no consensus among the respondents unless time intervals were combined. For example, 52% of responses indicated a 3-6 month time delay after a surgical index event, while 77% recommended a 3-9 month time-delay. This proportion of responses indicated a weak consensus, however, since the result was not significantly greater than 0.67. A moderate consensus (81%) of respondents recommended a 3-9 month time-delay after trauma not including a brain injury but in other cases (trauma with brain injury or after amputation) only weak consensus recommended this same time-delay.
DISCUSSION
The results of the survey indicate that management practices for prevention of HO in the elbow show different levels of agreement among the orthopaedic community. The survey reveals multiple points of divergence, even in the targeted academic community. Among all the practices queried in this survey, only four were strongly recommended and five were weakly recommended (Table 2) The four strongly recommended practices were: (1) treatment with some form of prophylaxis; (2) the use of radiation for prophylaxis; (3) the use of some form of NSAIDS for prophylaxis; and (4) the use of either 500 cGY to 700 cGY unfractionated dose when using radiation for prophylaxis. The consensus for some form of treatment reflects the current evidence that prophylaxis has been shown to consistently prevent HO formation in the postcontracture release setting as well as the acute traumatic setting. However, the lack of strong consensus recommendations for other responses suggests that there is strong agreement on the broader level of decisions regarding the management of HO in the elbow but less so with regard to the detailed elements of prophylactic treatment or surgical management. The survey does suggest that the use of radiation treatment presently is the leading preference of the elbow specialty community and further study to understand the efficacy and correct application of this technology is in order.
Radiation treatment inhibits the development of HO in the hip 16 but recent evidence is less clear on its efficacy in HO of the elbow and the appropriate dose to administer. 4--6,10--13,17,18 Nonetheless, there appears to be broad support for its value in elbow HO prophylaxis amongst survey respondents. Over 90% of the surgeons responding in this survey indicated the use of radiation in their own practices. However, the data also showed that no consensus exists on the radiation dose that should be delivered or whether to fractionate the radiation dose. A 700 cGy dose appears efficacious in cases of hip HO, 16 and a similar dosing regimen has been suggested for the elbow. 6 At the same time, questions exist as to whether this is the appropriate dose and if it leads to complications such as nonunions. 4,11--13 Seven hundred cGy was the most common dosage response (n ¼ 24 or 51%), but approximately 25% favored 500-600 cGy, suggesting the distribution of responses is skewed towards lower doses. It has not been shown in publication yet that these lower doses are effective in the prevention of HO in the elbow and a 500 cGy dose is not recommended after total hip arthroplasty. The apparent confusion between physician practices and evidence from elbow research to support these same practices strongly indicates that more research into the use and dose of radiation to prevent HO in the elbow is necessary. Potentially of equal importance is the area of treatment required and the technique of beam management to provide optimal efficacy with the least harm to uninvolved or at-risk tissues.
With regards to NSAIDS, the results indicate that the use of some form of NSAID is strongly recommended in the prevention of HO in the elbow, and a weak majority recommends its use over the longest interval in the survey, 1-3 months. A surprising result is that shorter treatment periods are preferred by only one third of the respondents despite the evidence in the literature supporting the efficacy of short-term (1-2 weeks) NSAID treatments in preventing HO in the hip and the subsequent potential to mitigate the severity of gastrointestinal side-effects. 16, 19, 20 The choice of prophylactic treatment is based on several factors related to the index event, patient age, HO risk factors, doctor choice, and others. Despite the complexity of decision making presented with patients at risk for the development of HO about the elbow, this survey indicates that 80%, or a moderate consensus of respondents, use Current Orthopaedic Practice www.c-orthopaedicpractice.com | 181 radiation and NSAIDs to prevent HO at the elbow. The fact that a moderate majority provided responses to both forms of prophylaxis suggests that the surgeon community chooses from one or the other, depending on the specific case. For example, in young patients with elbow trauma, NSAIDS may be preferred over radiation to avoid any longterm complications. Specifically, there exists a theoretical concern for radiation induced sarcoma in younger patients, although this has not been demonstrated in the radiation oncology literature even as a case report for single-dose treatment at the 700 cGy level. As stated earlier, radiation and NSAID prophylaxis are similarly effective and a recent analysis suggested that they are equally effective for different Booker classifications in the hip. In these cases, another factor to consider in the decision-making process is cost. Cost-effectiveness estimates suggest that radiation is 45 times more expensive. As complications persist, the costeffectiveness of NSAIDs declines relative to radiation, but the magnitude of the cost differential between the two treatments never falls below a 33-fold difference. 21 Another area of discrepancy highlighted by our survey is a lack of consensus regarding the time-delay for surgical excision of the HO in the elbow, even when the index event is defined. In all four cases, the 3-6 month period was the most common response, but it was favored by only 58% or fewer of the respondents when the index event was surgery or a trauma (no traumatic brain injury) and by 37% or fewer of the respondents when the trauma included traumatic brain injury and after amputation. The least agreement on the time-delay was observed with surgical excision after amputation. This result most likely reflects the fact that in many cases HO excision in the elbow may not affect the patient's overall functionality as greatly after amputation. As a result of the poor agreement on time-delays for surgical excision of HO in the elbow, we had to lump categorical variables to achieve even a weak consensus in three of the four categories: HO after surgery, HO after trauma with traumatic brain injury, and HO after amputation. Furthermore, while a classification scheme for HO has been proposed, 22 we were unable to find any well-powered prospective studies that relied on this classification scheme that recommend treatment courses for each severity grade of HO about the elbow.
This study investigated the practices of the U.S. community of academic orthopaedic surgeons in the prevention and For each treatment modality category and subcategory, the strength of the response was assessed on a scale from no consensus to strong consensus, with hypothetical proportions determining the limits of each level of consensus. One-sided binomial tests were used to determine if the observed proportion of responses was equal to or greater than the hypothesized proportions for each level of consensus. surgical management of HO in the elbow. Upper extremity orthopaedic surgeons generally agree on the use of prophylaxis, but there is less nationwide agreement on how to deliver these prophylactic regimens. This may result from the paucity of research on the treatment of HO in the elbow. Our survey results reflect the need for work to be performed in the decision tree ( Figure 2 ) for elbow HO prophylaxis to improve uniformity and efficacy of patient care in an effort to determine best practice guidelines for the orthopaedic community. Clearly, most research has been accomplished on HO in the hip and these practices extrapolated to the elbow. Of course, other factors could also be at the root of our results. A limitation of this work is that our survey did not address several of these other factors, including treatment of recurrent HO, whether factors like age, comorbidities, or the index event affect clinical decision-making. Additionally, our survey did not address whether bisphosphonate therapy and surgical technique could be considered prophylactic methods. This initial survey was purposefully concise to ensure a significant return by respondents and to capture the fundamental trends in treatment and management of HO in the elbow, which will lead to further research by this research team. Furthermore, the survey's scope, as it pertains to prophylaxis, was limited because the options for prophylaxis of HO in the elbow after any event consist of radiation therapy, NSAIDs, or possibly nothing. Perhaps in the near future clinicians will have more medical options to lower the rate of HO as a complication of surgery or trauma. Current research efforts aimed at defining the molecular pathophysiology of HO using the Fibrodysplasia Ossificans Progressiva (FOP) mouse model, 23 as well as the use of retinoic acid receptor agonists to prevent HO, 7 represent promising advances towards these new options for HO prophylaxis. 
